search
AstraZeneca
Trends
- 1AstraZeneca invests $2bn in cancer drug partnership with Summit Therapeutics●📈 Astrazeneca invests $2bn in cancer drug tie-up Astrazeneca has invested $2bn in US pharmaceutical firm Summit Therapeu
AstraZeneca has invested $2bn in US biotech firm Summit Therapeutics as part of a major cancer research collaboration. The FTSE 100 drugmaker agreed to buy 109,000 shares in the Nasdaq-listed company at $18.36 per share, funding a tie-up aimed at developing new cancer treatments.
- 2Hansoh lung cancer drug loses EU approval after AstraZeneca challenge▼Hansoh’s Tagrisso rival loses EU approval after AstraZeneca legal challenge
Hansoh Pharmaceutical's copy of AstraZeneca's lung cancer drug Tagrisso has lost its European Union approval following a successful legal challenge by AstraZeneca. The decision removes the Chinese drugmaker's competing osimertinib-like therapy from the EU market and represents a significant win for AstraZeneca in defending its blockbuster oncology franchise.